Skip to main content
. 2021 Apr 8;6(6):1732–1737. doi: 10.1016/j.ekir.2021.03.897

Table 2.

Teaching points

  • 1.

    Rapid diagnosis of aHUS is required to start TPE and eculizumab as quickly as possible.

  • 2.

    Genetic identification for complement mutation or polymorphism is essential for best management. CFH mutations are found in 60% of aHUS patients, whereas C3 mutations are only found in 2% to 10%.

  • 3.

    SARS-CoV-2 can trigger the development of a renal TMA.

  • 4.

    TPE does not seem to impede natural seroprotection against SARS-CoV-2.

aHUS, atypical hemolytic uremic syndrome; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TMA, thrombotic microangiopathy; TPE, therapeutic plasma exchange.